| Name | Title | Contact Details |
|---|
Aptevo Therapeutics is a biotech company primarily focused on bringing novel oncology and hematology therapeutics to market. We leverage the innovative ADAPTIR™ platform technology, a unique approach to cancer immunotherapy, to improve outcomes for cancer patients.
Allergan is a multi-specialty health care company focused on discovering, developing and commercializing innovative pharmaceuticals, biologics and medical devices that enable people to live life to its greatest potential — to see more clearly, move more freely, express themselves more fully. Our focus fosters deep engagement with medical specialists and we make it our business to listen closely to their needs so that together we can advance patient care. We combine this strategic focus with a diversified approach that enables us to follow our research and development into new specialty areas where unmet needs are significant. In partnership with the medical community, we bring to bear scientific excellence and rigor to deliver leading products that improve patient outcomes. We go above and beyond this to provide education and information, with the highest level of integrity, that helps patients to fully understand the choices available to them and make well-informed treatment decisions with their doctors. We know we are successful when doctors and patients place their trust in our products and our company, when our employees excel and when our efforts make a meaningful difference in the lives of the patients and communities we serve.
M3 is a biopharmaceutical company focused on development of therapeutics to address Alzheimer`s, Parkinson`s and Neurodegeneration.
Syntron Bioresearch, Inc. is a Carlsbad, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Alto Neuroscience is redefining psychiatry by developing personalized and highly effective medicines to help patients get better faster. Our artificial intelligence (AI)-enabled platform measures biomarkers like EEG and wearable data, behavioral patterns, genetics, and other factors to match patients with the treatment they are most likely to respond to. Our approach matches the right patient with the right Alto drug based on AI-derived brain biomarkers, redefining psychiatry at a time when the world needs it most.